Background {#Sec1}
==========

Malnutrition often occurs in severe acute stroke patients who are unable to take foods orally due to dysphagia or disturbed level of consciousness and who must receive enteral tube feeding (ETF) \[[@CR1]--[@CR3]\]. Malnutrition leads to the severity of the general condition and subsequently extended stay in hospital or in-hospital mortality \[[@CR4]--[@CR7]\]. Malnutrition may contribute to a weakened immune system and causes infection to occur \[[@CR8]\]. Acute inflammation associated with infection exacerbates hypoproteinemia, and the clinical outcomes in patients with severe hypoproteinemia are generally poor. If malnutrition occurs in a patient, it should be treated and improved as soon as possible. Inflammation must be attenuated as soon as possible. However, it has not been established on how to improve hypoproteinemia rapidly \[[@CR9]\]. Larger volumes of protein intake in the diet do not always lead to rapid improvement of hypoproteinemia and cessation of inflammation due to anabolic resistance in a severe clinical state \[[@CR10], [@CR11]\]. Leucine is one of the essential amino acids and one of the branched-chain amino acids (BCAA) \[[@CR12]\], and previous studies have reported that leucine enriched BCAA supplement may attenuate inflammation, enhance protein synthesis \[[@CR13]--[@CR15]\] and may be useful in recovering muscle mass and strength and in promoting rehabilitation \[[@CR13], [@CR16]--[@CR19]\]. Our study aimed to investigate whether leucine-enriched BCAA dietary supplement (LEBDs) could quickly increase serum levels of albumin (Alb) or transthyretin (TTR) and quickly decrease high-sensitivity C-reactive protein (CRP) in the development of severe malnutrition within a few days after stroke onset compared to standard BCAA dietary supplement (SBDs).

Methods {#Sec2}
=======

For the retrospective observational study, we included acute stroke patients who: 1) were admitted between August 2016 and July 2017, 2) started ETF on the second day and continued to undergo ETF for 7 days or longer after admission, 3) underwent blood examination on admission, the fifth day and the seventh day, and 4) started to receive LEBDs or SBDs to improve severe malnutrition on the fifth day. We defined severe malnutrition as rapid progression of hypoproteinemia: decrease of TTR to less than 15 mg/dl, as TTR is a rapid turnover protein \[[@CR20]\]. Patients started to receive LEBDs or SBDs twice a day on the fifth day added to baseline enteral nutrients.

Exclusion criteria {#Sec3}
------------------

We excluded from our analysis patients who: 1) died due to very severe stroke within 7 days after its onset, 2) could take foods orally on admission, or 3) did not undergo a thorough blood examination.

Target calories {#Sec4}
---------------

We calculated the target calories for patients according to the Harris-Benedict Equation (HBE) \[[@CR21]\].

Enteral nutrients {#Sec5}
-----------------

We started to administer enteral nutrients on the second day of admission. Enteral nutrients (EN) we used to be IMPACT (Nestle Japan Co. Ltd.), PEPTAMEN AF (Nestle Japan Co. Ltd.), MEIN (Meiji Co. Ltd., Japan) or RENALEN MP (Meiji Co. Ltd., Japan). IMPACT includes contents that consist of protein of 14 g (arginine-enhanced), containing leucine of 0.975 g, lipid of 7.0 g, containing middle-chain triglyceride (MCT) of 1.5 g, and carbohydrates of 33.5 g against 250 kcal per 250 ml of one pack. PEPTAMEN AF includes contents that consist of protein of 19 g, containing leucine of 2.03 g and whey peptide, lipid of 13.2 g, containing MCT of 6.7 g, and carbohydrates of 26.4 g against 300 kcal per 200 ml of one pack. MEIN consists of protein of 10 g, containing leucine of 0.96 g and whey peptide, lipid of 5.6 g, containing MCT of 1.2 g, and carbohydrates of 29.8 g, containing palatinose, against 200 kcal per 200 ml of one pack. Renalen MP consists of protein of 14 g, containing leucine of 1.32 g, lipid of 11.2 g, containing MCT of 2.3 g, and carbohydrates of 64.0 g, containing palatinose, against 400 kcal per 250 ml of one pack. Palatinose is a disaccharide that consists of one glucose and one fructose, and it has a low glycemic index. Enteral nutrients except for RENALEN MP were protein-rich nutrients. Leucine enriched BCAA dietary supplement (LEBDs) (Leucine Plus, Nestle, and Ajinomoto, Japan) consists of protein of 8 g, containing 1.44 g of leucine, and sugar of 18.5 g, against 200 kcal per 100 ml of one pack, and standard BCAA dietary supplement (SBDs) (Meibalance Mini, Meiji Co. Ltd., Japan) consists of protein of 7.5 g, containing leucine of 0.72 g and sugar of 29.3 g, against 200 kcal of one pack (Table [1](#Tab1){ref-type="table"}). Protein volume in LEBDs was almost the same as in SBDs. Table 1Contents of leucine enriched and standard BCAA dietary supplementsDietary supplementLeucine enriched BCAAStandard BCAAVolume (1 pack)100 ml125 mlCalories (1 pack)200 kcal200 kcalProtein8.0 g7.5 g BCAA2.07 g1.58  Leucine**1.44 g**0.72  Valine0.36 g0.48 Isoluecine0.27 g0.38Lipid10.3 g5.6 g MCT3.3 gno information n-6 FA2.1 gno information n-3 FA0.3 gno informationCarobohydrates20.4 g31.8 g Sugar18.5 g29.3 g Dietary fiber1.9 g2.5 gWater70 g93.7 gNa110 mg110 mgK127 mg120 mg*BCAA* Branched chain amino acid, *kcal* kcalorie, *MCT* Middle chain fatty acid, *FA* Fatty acid, *Na* Natrium, *K* Potassium

Evaluation {#Sec6}
----------

We evaluated patient features, TTR, Alb, and high-sensitivity CRP on admission, the fifth day, the 7th day, because previous studies have reported CRP elevation and decrease in Alb or TTR in patients with severe inflammation or severe acute conditions \[[@CR22]--[@CR24]\]. Besides, we evaluated Glasgow Coma Scale (GCS) \[[@CR25]\], in-hospital clinical outcome, hospitalization days, and serum Cre on admission, the fifth day, the 7th day, because deterioration of renal function was a possible adverse effect of protein-rich EN.

Statistical analysis {#Sec7}
--------------------

Non-normally distributed continuous variables were expressed as the median and interquartile range (IQR). Differences between LEBDs and SBDs were compared using a Fisher's exact test for categorical variables and a Wilcoxon rank-sum test for non-parametric data. For a comparison of paired variables, we used a Wilcoxon signed-rank test for non-parametric data. We performed a two-sided test for unpaired variables, a one-sided test for paired variables, and considered a probability of less than 0.05 statistically significant. We used the JMP (version 15.1) program to perform the statistical analysis.

Results {#Sec8}
=======

During the study period, we treated 800 acute stroke patients in our institution. Among patients who underwent ETF on the second day, the TTR level on the fifth day was less than 15 mg/dl in 29 patients, and the 15 patients started to receive LEBDs and the 14 patients started to receive SBDs on the 5th day. There were no differences in patients' characteristics between the two groups. Their median age was older than 80 years. In LEBDs and SBDs groups, the median GCS on admission was 9 and 9.5, respectively, and they suffered from impaired consciousness.

In LEBDs and SBDs groups, the median Alb was 3.5 and 3.3 g/dl (ns), TTR was 12.7 and 10.7 mg/dl (ns), and CRP was 1.02 and 0.673 mg/dl (ns) on admission, respectively (Table [2](#Tab2){ref-type="table"}). In LEBDs group, patients received baseline protein intake of 1.2 (g/kg/day) by enteral nutrition (Table [3](#Tab3){ref-type="table"}). However, the median Alb decreased to 2.6 g/dl (*p* \<  0.0001) and the median TTR decreased to 11.9 mg/dl (*p* \<  0.001), and CRP increased to 5.337 mg/dl (*p* \<  0.05) on the fifth day. We added the LEBDs (2.88 g of leucine/400 kcal/200 ml/day) to baseline EN. On the 7th day, TTR increased (*p* \<  0.001) and CRP decreased (*p* \<  0.05) although Alb did not improve (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}; left) (Table [4](#Tab4){ref-type="table"}). In SBDs group, patients received baseline protein intake of 1.4 (g/kg/day) by enteral nutrition (Table [3](#Tab3){ref-type="table"}). However, the median Alb decreased to 2.6 g/dl (*p* \<  0.0001) and the median TTR decreased to 9.7 mg/dl (*p* \< 0.05), and the median CRP increased to 4.077 (*p* \< 0.05) on the fifth day. We added the SBDs (1.44 g of leucine/400 kcal/250 ml/day) to baseline EN. On the 7th day, Alb, TTR and CRP did not improve (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}; right) (Table [4](#Tab4){ref-type="table"}). The serum TTR level on the 7th day was higher in LEBDs than in SBDs, although there were no differences in TTR on the 5th day between LEBDs and SBDs (Table [2](#Tab2){ref-type="table"}). Table 2Patients' characteristics in Leucine enriched and standard BCAA dietary supplementsDietary supplementLeucine enriched BCAAStandard BCAAn1514pAge, median (IQR) years82 (77--92)80.5 (77.8--86.3)nsFemale (Sex), n (%)9 (60%)9 (64.3%)nsGCS, median (IQR)9 (7--14)9.5 (6.25--13)nsBMI, median (IQR)21.8 (17.6--23.5)19.8 (16.4--22.9)ns**On admission** Alb, median (IQR)3.5 (3--4.1)3.3 (3--3.7)ns TTR, median (IQR)12.7 (12--17.2)10.7 (8.25--13.0)ns CRP, median (IQR)1.02 (0.115--3.705)0.673 (0.142--2.961)ns Cre, median (IQR)0.78 (0.71--1.04)0.695 (0.51--0.91)ns**On the 5th day** Alb, median (IQR)2.6 (2.4--3.0)2.6 (2.3--2.9)ns TTR, median (IQR)11.8 (7.3--12.6)9.65 (7.83--11.9)ns CRP, median (IQR)5.243 (3.038--10.404)4.077 (0.700--6.369)ns Cre, median (IQR)0.74 (0.65--2.06)0.63 (0.50--0.88)\< 0.05**On the 7th day** Alb, median (IQR)2.6 (2.4--2.9)2.5 (2.2--2.8)ns TTR, median (IQR)15.7 (10.2--20.2)10.7 (8.3--12)\< 0.05 CRP, median (IQR)4.774 (1.183--6.563)2.459 (0.921--5.656)ns Cre, median (IQR)0.79 (0.63--2.03)0.62 (0.47--0.86)ns**Enteral nutrient (baseline)** Impact13 Peptamen AF47 Mein73 Renalen MP31*BCAA* Branched chain amino acid, *GCS* Glasgow Coma Scale, *BMI* body mass index (kg/m^2^), *Cre* creatinine (mg/dl), *p* probability, *ns* not significantTable 3Patients charactreristics in leucine enriched and standard BCAA dietary supplementsCaseGCS on admissionDiagnosisMedical historyBMIBWCre on admissioneGFR on admissionT-CHO on admissionTG on admissionmRS before strokeEN (1 pack)Protein intake by EN (g/day)Protein intake by EN (g/kg/day)Calorie intake (/day)Target calorie (/day)OutcomeHospitalization (days)**Leucine enriched BCAA dietary supplement** 17Cardioembolic strokeAf, HT, Asthma23.3620.7358.15201940Impact (250 k, P14g)701.112501515Discharge8 213Ischemic stroke (Large vessel occlusion)HT, DM, ASO, post-surgery of rectal cancer24.5650.7874.032412030Peptamen AF (300 k, P19g)75.61.212001434Discharge15 315Intracerebral hemorrhage (hypertensive)HT, CRF (HD), hypothroidism18.4506.966.5697583Renalen MP (400 k, P14g)420.812001239Discharge11 49Intracerebral hemorrhage (hypertensive)HT, ASO21.8491.0452.47174563Peptamen AF (300 k, P19g)75.61.512001122Discharge14 511Cardioembolic strokeHT, DM, CKD, Anemia18.3441.7521.302061015Renalen MP (400 k/P)421.012001328Discharge12 612Cardioembolic strokeAf, HT, DM, MVR17.6450.7457.51139420Peptamen AF (300 k, P19g)75.61.712001344Discharge8 77Intracerebral hemorrhage (hypertensive)HT, DL, CKD13.9300.7156.44286653MEIN (200 k, P10g)602.012001005Discharge12 83Intracerebral hemorrhage (hypertensive)Paf, HT, DM, Dementia, DVT23.5640.6880.80159872MEIN (200 k, P10g)701.114001803In-hospital death8 99Ischemic stroke (Large vessel occlusion)HT, DL, CKD, CHF20.6440.8645.762561245MEIN (200 k, P10g)601.412001081Discharge14 105Intracerebral hemorrhage (hypertensive)HT, DL, ASO, OMI (post-CABG), post-CAS23.4580.9250.611371670MEIN (200 k, P10g)701.214001356Discharge10 1114Ischemic stroke (Large vessel occlusion)Af, HT, DM, DL, CRF, post-CABG, stent gradt for AAA22.3579.354.75119923MEIN (200 k, P10g)701.214001521Discharge17 1215Cardioembolic strokeAf, HT, left IC occlusion, breast cancer25.7570.5971.84216650MEIN (200 k, P10g)701.214001563Discharge13 137Cardioembolic strokeAf, HT, DL, IGT, Lung cancer, DVT, intracerebral aneurysm (unruptured)23.5550.7656.391581020Renalen MP (400 k, P14g)420.812001293In-hospital death21 1414Cardioembolic strokePaf15.8370.7059.181881283Peptamen AF (300 k, P19g)75.62.012001063Discharge16 158Cardioembolic strokeHT, right MCA stenosis17.3390.8347.72210584MEIN (200 k, P10g)501.31000943Discharge8Median921.8500.7856.4188923701.21200132812**Standard BCAA dietary supplement** 17Ischemic stroke (Large vessel occlusion)HT, DL, Paf22.6670.7771.7206360Impact (250 k, P14g)701.015001628Discharge10 213Cardioembolic strokeAf, HT, DM, Obesity, OCI25.8620.4992.8161630Peptamen AF (300 k, P19g)75.61.212001321Discharge11 314Cardioembolic strokeDM, OCI, AAA16.5450.6591.11591052Peptamen AF (300 k, P19g)94.52.115001350Discharge14 43Cardioembolic strokeHT, DM, HL, CABG,OCI, Basedow,19.5441.1535.2133904MEIN (200 k, P10g)601.412001077Discharge8 54Cardioembolic strokePaf, HT, HL, DM23.8500.944.42351162Impact (250 k, P14g)561.110001036Discharge9 613Ischemic stroke (small vessel occlusion)HT, AP, OCI, Dementia, DVT22.0550.6860.9241854MEIN (200 k, P10g)601.112001286Discharge10 712Intracerebral hemorrhage (hypertensive)HT, DVT20.0450.7158.12051333MEIN (200 k, P10g)501.110001258Discharge10 88Cardioembolic strokeAf, HT, OCI, DL24.0540.4792.42061134Peptamen AF (300 k, P19g)75.61.412001340Discharge9 911Intracerebral hemorrhage (hypertensive)HT14.5390.4891.7182340Impact (250 k, P14g)561.410001054Discharge9 108Ischemic stroke (Large vessel occlusion)HT, DM, DL21.8630.697.5223984Peptamen AF (300 k, P19g)94.51.515001590Discharge18 113Cardioembolic strokePaf, HT,LC15.9431.6830.81261Renalen MP (400 k, P14g)350.810001111In-hospital death10 129Ischemic stroke (Large vessel occlusion)HT,DM,OCI, DL, Dydrocephalus, ASO18.7420.7256.81891715Peptamen AF (300 k, P19g)75.61.812001238Discharge7 1310Ischemic stroke (small vessel occlusion)HT, SAH15.0360.5283.7163964Peptamen AF (300 k, P19g)75.62.112001099Discharge7 1413Cardioembolic strokeHT, HL, DM18.1480.9260.6159750Peptamen AF (300 k, P19g)75.61.612001218Discharge22Median9.519.746.50.7066.318696372.81.41200124810*BCAA* branced-chain amino acids, *P* protein, *GCS* Glasgow Coma Scale, *BMI* body mass index (kg/m2), *BW* body weight (kg), *Cre* serum creatinine (mg/dl), *eGFR* estimated Glomerular Filtration Rate (mL/min/1.73 m2), *T-CHO* total cholesterol (mg/dl), *TG* triglyceride (mg/dl), *mRS* modified Rankin scale, *EN* enteral nutrient, *k* kcal, *Af* atrial filtration, *HT* hypertension, *DM* diabetes mellitus, *CRF* chronic renal failure, *HD* hemodyalysis, *ASO* arteriosclerosis obliterans, *CKD* chronic kidney disease, *MVR* mitral valve replacement, *DL* dyslipidemia, *DVT* deep venous thrombosis, *CHF* chronic heart failure, *OMI* old myocardial infarction, *Paf* paroxysmal af, *CABG* coronary aorta bypass surgery, *CAS* carotid artery stenting, *AAA* abdominal aorta aneurysm, *IC* internal carotid artery, *IGT* impaired glucose tolerance, *MCA* middle cerebral arteryFig. 1Serial changes of serum TTR on admission, on the fifth day, and the seventh day. One-sided Wilcoxon signed-rank test was performed. Left: Leucine enriched BCAA dietary supplement, Right: Standard BCAA dietary supplement, BCAA: branched-chain amino acid, TTR: transthyretinFig. 2Serial changes of serum Alb on admission, on the fifth day and the seventh day. As shown, a one-sided Wilcoxon signed-rank test was performed. Left: Leucine enriched BCAA dietary supplement, Right: Standard BCAA dietary supplement, BCAA: branched-chain amino acid, Alb: albuminFig. 3Serial changes of serum CRP on admission, on the fifth day and the seventh day. One-sided Wilcoxon signed-rank test was performed. Left: Leucine enriched BCAA dietary supplement, Right: Standard BCAA dietary supplement, BCAA: branched-chain amino acid, CRP: high-sensitivity C-reactive proteinTable 4Changes of serum markers in leucine enriched and standard BCAA dietary supplementsCaseTTR on admissionTTR on the fifth dayTTR on the seventh dayAlb on admissionAlb on the fifth dayAlb on the seventh dayCRP on admissionCRP on the fifth dayCRP on the seventh dayCre on admissionCre on the fifth dayCre on the seventh day**Leucine enriched BCAA dietary supplement** 113.114.023.14.02.93.28.8313.0381.1830.730.530.52 216.110.815.74.33.12.60.87016.3766.1610.781.251.16 312.07.311.33.02.32.51.86210.4044.7746.965.675.79 412.33.54.44.12.22.00.32438.07921.2801.043.972.03 512.712.413.32.82.12.11.0202.1600.9411.752.061.83 69.07.310.23.02.62.43.7055.4312.1310.740.740.79 717.212.420.53.52.62.70.0362.0090.3850.710.690.62 87.96.78.23.42.52.68.16824.71915.1360.680.922.09 98.28.417.23.22.42.61.6738.2851.4570.860.700.65 1024.711.910.94.22.72.10.0166.4695.8490.921.010.82 1116.913.320.24.13.13.00.2735.2434.6059.354.745.34 1223.312.719.64.22.82.90.0934.0781.0450.590.540.63 1312.512.620.43.33.03.49.2655.1998.8870.760.560.64 1417.811.815.92.92.42.51.2124.0666.5630.700.650.50 1512.210.78.13.73.42.90.1150.5986.0460.830.700.64Median12.911.915.83.52.62.61.1165.3374.6900.770.830.81MDB A-5−3.6 (*p* \< 0.001)−0.9 (*p* \< 0.0001)4.0 (*p* \< 0.01)−0.05 (ns)MDB 5--74.1 (*p* \< 0.001)0.1 (ns)−1.9 (*p* \< 0.05)−0.05 (ns)**Standard BCAA dietary supplement** 111.811.010.44.02.62.41.3325.3013.2680.770.720.70 28.110.411.12.92.32.23.7960.5550.7910.490.540.65 38.38.312.13.02.52.70.8225.9241.7210.650.510.51 48.09.510.13.02.02.13.3884.0582.4191.151.101.08 510.48.48.93.72.62.70.4073.3962.4990.90.850.87 620.313.213.63.73.33.10.0500.1490.2100.680.630.64 717.113.612.03.52.92.70.0284.3275.8640.710.620.60 85.86.26.62.82.32.38.3274.0955.5870.470.410.42 912.812.812.04.43.53.40.5240.7480.9840.480.450.40 1010.69.810.92.92.32.22.3457.7033.0410.600.400.39 1110.73.14.13.21.51.50.17223.42818.5591.681.611.85 1212.411.612.03.43.02.90.2270.2270.9640.720.640.57 138.88.810.53.02.62.60.0150.8120.1960.520.520.48 1413.56.44.13.52.52.22.81930.90533.4140.920.970.85Median10.79.710.73.32.62.50.6734.0772.4590.700.630.62MDB A-5−0.8 (\< 0.05)−0.6 (*p* \< 0.0001)1.893 (*p* \< 0.05)−0.015 (*p* \< 0.01)MDB 5--70.45 (ns)−0.1 (ns)−0.278 (ns)− 0.05 (ns)*BCAA* branched-chain amino acids, *TTR* transthretin (mg/dl), *Alb* albumin (g/dl), *CRP* high-sensitivity C-reactive protein (mg/dl), *Cre* creatinine (mg/dl), *MDB A-5* median difference between on admission and the fifth day, *MDB 5--7* median difference between on the fifth and the seventh day, *p* probability, *ns* not significant

In LEBDs group, the median creatinine (Cre) and estimated glomerular filtration rate (eGFR) on admission were 0.78 (mg/dl), and 56.4 (mL/min/1.73m^2^), respectively. In 12 of the 15 patients, eGFR was less than 60 (mL/min/1.73 m2). The 12 patients suffered from renal dysfunction on admission (Table [3](#Tab3){ref-type="table"}). In LEBDs group, the median target calorie and real calorie intake by EN was 1328 and 1200 kcal/day, respectively. The calorie status was 90.4% of the plan on the fifth day. We used protein-rich EN except for REANALEN MP in 12 of the 15 patients (Table [3](#Tab3){ref-type="table"}). In SBDs group, their median Cre and eGFR, on admission were 0.70 (mg/dl), and 66.3 (mL/min/1.73 m2). In 5 of the 14 patients, eGFR was less than 60 (mL/min/1.73m^2^). The 5 patients suffered from renal dysfunction on admission (Table [3](#Tab3){ref-type="table"}). In SBDs group, the median target calorie and real calorie intake by EN was 1248 and 1200 kcal/day, respectively. The calorie status was 96.2% of the plan on the fifth day. We used protein-rich EN except for REANALEN MP in 13 of the 14 patients (Table [3](#Tab3){ref-type="table"}).

Overall renal function did not deteriorate except for two cases in LEBDs group (Table [4](#Tab4){ref-type="table"}). In Case 2 and 4 in LEBDs group, serum Cre level acutely rose on the fifth day, and protein per day by PEPTAMEN AF was reduced from 75.6 to 56.7 g from the fifth day. The LEBDs was added on protein of 56.7 g by PEPTAMEN AF in case 2 and 4, and their Cre level did not deteriorate on the seventh day (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}).

In LEBDs, 13 (86.7%) of the 15 patients discharged within 17 days, and they were transferred to comprehensive rehabilitation centers after their TTR and CRP were improving. Two of the 15 patients died on the eighth day and the twenty-first day, respectively. Median hospitalization in LEBDs was 12 days. In SBDs, 12 (85.7%) of the 14 patients discharged within 17 days, and they were transferred to comprehensive rehabilitation centers, although neither TTR nor CRP were not improving. One of the 14 patients died on the tenth day. Median hospitalization in SBDs was 10 days (Table [3](#Tab3){ref-type="table"}).

Discussion {#Sec9}
==========

Our results demonstrate that quick improvements on the transthyretin and CRP level were observed in acute stroke patients who received leucine enriched BCAA dietary supplement added to baseline enteral nutrients.

Our patients were very elderly, suffered from impaired consciousness and renal dysfunction, and malnutrition within the 5 days of admission. We used EN containing leucine and MCT and provided protein of median 1.2 g or more (/kg/day) in the 29 patients \[[@CR11]\]. Their TTR and Alb level, however, declined. Serum Cre acutely rose in two of the 25 patients administered with protein-rich EN, and protein-rich EN-induced deterioration of renal function, therefore, must be considered. We administered the LEBDs in the 15 patients, and 13 of them achieved an early discharge to comprehensive rehabilitation centers within 17 days after TTR and CRP were improving. Their clinical course was not usual. Thirteen of the 14 patients with SBDs survived and were transferred to comprehensive rehabilitation hospitals without improvements of TTR and CRP. SBDs might contribute to prevention of further deterioration of TTR, Alb and CRP, although SBDs could not improve them.

We supposed that the LEBDs had a quick effect on improvement of hypoproteinemia and cessation of inflammation in the 15 patients. After administration of the LEBDs, the TTR level rose soon, and the CRP level decreased soon, probably because leucine enriched BCAA played critical roles in the regulation of energy homeostasis, nutrition metabolism, gut health, immunity as they acted as potential anti-inflammatory mediators \[[@CR26]--[@CR28]\], further helped attenuate inflammation and enhance protein synthesis \[[@CR13], [@CR27], [@CR28]\]. The Alb level did not change soon after the administration of the LEBDs, as the Alb level usually improves slowly. The LEBDs likely provides benefits with malnutrition patients in a stroke care unit or intensive care unit.

Study limitations {#Sec10}
-----------------

Our study had several limitations. Our study included a small number of patients. Our study was not a prospective randomized controlled study but a retrospective observational cohort study of routine medical care. We, therefore, did not have a placebo-controlled group without BCAA supplement, and we compared LEBDs group with SBDs group. The LEBDs contained MCT or n-3 fatty acids; no information, however, was provided in SBDs. Our patients started to use different types of enteral nutrients as the baseline. All patients were likely of Japanese ancestry; therefore, not representative of the general population. Our study investigated short-term outcomes of blood examinations, in-hospital death, and hospitalization days but did not study the long-term effect. To confirm our results, therefore, future prospective studies are required in patients with the standardization of enteral nutrients.

Conclusion {#Sec11}
==========

In acute stroke patients receiving leucine enriched BCAA dietary supplement, quick improvements in transthyretin and CRP were observed compared to patients with standard BCAA dietary supplement. The results warrant the further clinical application of the LEBDs in acute patients with malnutrition.
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